Full-Time

Senior Engineer

Combination Products, Process Engineering

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$119.2k - $147.9k/yr

+ Bonus + Stock-based long-term incentives

Senior, Expert

Cambridge, MA, USA

Category
Process Engineering
Required Skills
Risk Management
Requirements
  • High school diploma / GED and 10 years of Engineering and/or Operations experience; OR
  • Associate’s degree and 8 years of Engineering and/or Operations experience; Or
  • Bachelor’s degree and 4 years of Engineering and/or Operations experience; Or
  • Master’s degree and 2 years of Engineering and/or Operations experience; Or
  • Doctorate degree
Responsibilities
  • Lead process characterization of prefilled syringe delivery systems, including packaging, labeling, and accessories.
  • Lead process improvements, conduct analytical failure analysis, and implement process solutions.
  • Author technical records and ensure they are appropriately maintained in the e.g. Device Master record (DMR)/Master Manufacturing Record (MMR)
  • Author technical content in Tech Transfer.
  • Represent Process engineering within a large network/matrix organization.
  • Evaluate test methods, prototype designs, and optimize products and processes using DOE and statistical techniques.
  • Monitor project progress, identify risks, and implement mitigation strategies to ensure project landmarks and timelines are met.
  • Key player in fostering a collaborative and innovative team environment to drive continuous improvement and operational excellence.
Desired Qualifications
  • Bachelor's degree in engineering or other science-related field with 7+ years of relevant work experience with 5+ years of experience in operations/manufacturing environment.
  • Medical device industry experience and regulated work environment experience.
  • A background in developing and commercialization of medical devices and knowledge of manufacturing processes.
  • At a minimum familiar with the following standards and regulations: Quality System Regulation – 21CFR820, Risk Management – ISO 14971, EU Medical Device requirements – Council Directive 93/42/EEC.
  • Strong understanding and experience in design controls, failure investigation, initiating and bringing complex projects to conclusion.
  • Excellent communication and technical writing skills.
  • Ability to work independently and across functional teams.
  • Strong inter-personal and communication skills, with the ability to effectively collaborate with diverse teams and partners.
  • Extensive knowledge of design controls and regulatory requirements for medical devices and combination products.
  • Background in Combination product manufacturing processes and knowledge of developing and commercializing medical devices.
  • Familiarity with standards and regulations such as Quality System Regulation – 21CFR820, Risk Management – ISO 14971, and EU Medical Device requirements – Council Directive 93/42/EEC.
  • Strong understanding and experience in process failure investigation and project management.
  • Preferably have technical flair and are familiar with technical drawings and construction.
  • Demonstrated proficiency in project management.
  • Preferably have Strong background in statistical analysis (experience with e.g. Minitab, JMP is an advantage)
  • Preferably have experience with Kistler Maxymos monitoring systems.
  • Strong problem-solving skills and the ability to make sound technical decisions.
  • Ability to thrive in a fast-paced, dynamic environment and manage multiple priorities.

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care and outcomes by providing effective therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.